Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$84.93 USD

84.93
2,385,980

+0.61 (0.72%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $85.09 +0.16 (0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Glaxo (GSK) Q4 Earnings Lag Estimates, Shingrix Back on Track

by Zacks Equity Research

Glaxo's (GSK) Shingrix shows strong recovery during the quarter. However, negative impact of COVID-19 hurts sales of Pharmaceuticals and Consumer Healthcare segment.

Kevin Cook headshot

Biotech Bonanza: COVID Launches Science at Warp Speed

by Kevin Cook

From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.

Has Moderna (MRNA) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (MRNA) Outperforming Other Medical Stocks This Year?

Moderna (MRNA) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed the most recent trading day at $158.58, moving +0.7% from the previous trading session.

Vertex (VRTX) Q4 Earnings Miss, Revenues Beat Estimates

by Zacks Equity Research

Vertex (VRTX) reports missing earnings estimates in the fourth quarter of 2020, while revenues surpass the same. The company provides revenues guidance for 2021.

J&J's (JNJ) Coronavirus Vaccine Shows 66% Efficacy in Phase III

by Zacks Equity Research

J&J's (JNJ) phase III ENSEMBLE study on its single-dose COVID-19 vaccine candidate meets all primary and key secondary endpoints.

Sweta Jaiswal, FRM headshot

Novavax (NVAX) ETFs to Rise on Impressive Coronavirus Vaccine Update

by Sweta Jaiswal, FRM

Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.

Personal Income Increased in December

by Zacks Equity Research

Personal Income Increased in December

Novavax's (NVAX) COVID-19 Vaccine 89.3% Effective in U.K. Study

by Zacks Equity Research

Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, proves its vaccine efficacy of 89.3% in late-stage study in the United Kingdom. Stock rises in after-hours trading.

Mark Vickery headshot

Economic Prints, Q4 Reports Up for Lilly, CAT; J&J Posts Phase-3 Data

by Mark Vickery

With the GameStop (GME) short-squeeze saga continuing, market indexes work to regain their equilibrium.

Mark Vickery headshot

Markets Bounce Back; Visa (V) Beats, Mondelez (MDLZ) Meets

by Mark Vickery

The Dow, which reached +650 points at its intra-day high, closed up 300 points, or around 1%. The S&P 500 followed suit, finishing up +37 points.

Dr. Reddy's (RDY) Ends Kuwait Study on Avigan for COVID-19

by Zacks Equity Research

Dr. Reddy's (RDY) and Global Response Aid FZCO terminate the Avigan study conducted in Kuwait, focused on moderate-to-severe COVID patients in a hospital setting.

Is First Trust Multi Cap Growth AlphaDEX ETF (FAD) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FAD

Sweta Killa headshot

JNJ Touches New Highs Post Solid Q4 Earnings: ETFs in Focus

by Sweta Killa

The solid results coupled with upbeat vaccine data optimism pushed JNJ shares to all-time high.

Regeneron (REGN) Reports Positive Data on Cocktail for COVID-19

by Zacks Equity Research

Regeneron (REGN) reports positive initial results from a phase III study evaluating REGEN-COV antibody cocktail as a passive vaccine for the prevention of people at high risk of COVID-19 infection.

Biotech Stock Roundup: Coronavirus Updates From REGN, MRNA, & Other Updates

by Zacks Equity Research

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Moderna (MRNA) and Exelixis (EXEL).

The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech and AstraZeneca

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech and AstraZeneca

Sweta Jaiswal, FRM headshot

Can Moderna ETFs Gain on COVID Vaccine Update Against Variants?

by Sweta Jaiswal, FRM

Positive coronavirus vaccine update from Moderna (MRNA) has hogged investors' attention.

How Long Will Coronavirus Vaccine Drive Moderna (MRNA) Stock?

by Zacks Equity Research

Moderna's (MRNA) progress with coronavirus vaccine development and its approval is driving its share prices for the past year. Will the trend continue?

The Zacks Analyst Blog Highlights: NIKE, Amgen, Morgan Stanley, Vertex Pharma and Moderna

by Zacks Equity Research

The Zacks Analyst Blog Highlights: NIKE, Amgen, Morgan Stanley, Vertex Pharma and Moderna

Sheraz Mian headshot

Top Stock Reports for NIKE, Amgen & Morgan Stanley

by Sheraz Mian

Today's Research Daily features new research reports on 12 major stocks, including NIKE (NKE), Amgen (AMGN), and Morgan Stanley (MS).

Pfizer (PFE) to Supply 40M Doses of Coronavirus Vaccine to COVAX

by Zacks Equity Research

Pfizer (PFE) and BioNTech inks an agreement with COVAX to supply up to 40 million doses of their COVID-19 vaccine, BNT162b2.

Markets Await Economic and Earnings Data

by Zacks Equity Research

Markets Await Economic and Earnings Data

Mark Vickery headshot

Quiet Before the Q4 Earnings Storm

by Mark Vickery

Big Tech reports earnings later this week, with Apple (AAPL) and Tesla (TSLA) among the companies putting out quarterly results. We see the Nasdaq +120 points an hour before the opening bell.

VBI Vaccines (VBIV) Provides Updates on COVID-19 Vaccine

by Zacks Equity Research

VBI Vaccines (VBIV) plans to begin a phase I/II study of monovalent vaccine candidate, VBI-2902, in the first quarter of 2021.